StrokeSTARTNCT07254377
Design and Validation of Innovative Strategies Based on Dual-Task Approach
A study testing Dual Task exercise and Physical therapy in people with Stroke and Multiple Sclerosis, run by I.R.C.C.S. Fondazione Santa Lucia at 1 site in Italy.
Trial summary
People affected by Stroke, Multiple Sclerosis (MS), and Parkinson's disease (PD) share severe and complex disabilities. Widespread neuro-inflammatory processes represent an important pathogenetic component in all three conditions. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Stroke, Multiple Sclerosis, Parkinson Disease
- What is being tested?
- Dual Task exercise and Physical therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 1 siteItaly
- Study dates
- 1 Nov 2025to 28 Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of stroke outcomes, Multiple Sclerosis (MS), or Parkinson's disease (PD).
- For stroke outcomes: patients must be able to walk independently for at least 6 minutes without resting.
- For MS: diagnosis according to the 2017 revised McDonald criteria; relapsing-remitting or secondary progressive forms; age 25-65 years; Expanded Disability Status Scale score between 2.5 and 6.0.
- For PD: idiopathic Parkinson's disease.
- For each neurological condition, half of the participants must have had Severe Acute Respiratory Syndrome Coronavirus 2 infection with neurological symptoms attributable to CNS involvement lasting at least 4 weeks.
- Ability to provide informed consent.
Who cannot join
- Cognitive or motor comobidity;
- Severe visual or hearing impairments that may compromise understanding of exercises
- Language impairments, such as aphasia
- Inability to walk independently
Trial locations and contacts
1 site in 1 country.
About this study
Official title: START: Design and Validation of Innovative Strategies Based on Dual-Task Approach for Neuro- Rehabilitation Technologically-supported in People With Chronic Neuro-inflammatory Disease
People affected by Stroke, Multiple Sclerosis (MS), and Parkinson's disease (PD) share severe and complex disabilities. Widespread neuro-inflammatory processes represent an important pathogenetic component in all three conditions. The potential overlap with neurological complications of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has further contributed to the worsening of functional impairment. Since pharmacological therapies have limited or negligible effects in these disorders, neurorehabilitation plays a crucial role in restoring and maintaining adequate functional abilities. In this context, dual-task strategies have attracted growing interest, but their effectiveness has not been adequately assessed in the above neurological conditions-and not at all in individuals with long-term sequelae of SARS-CoV-2 infection.
Based on these premises, the objectives of this research project are:
Read more
- to design rehabilitation strategies using the dual-task approach in its various forms (dual motor task, dual cognitive task, and combined motor-cognitive task) and to conduct feasibility tests in small groups of individuals affected by stroke, MS, PD, or long-term Coronavirus Disease 2019 (COVID-19) sequelae;
- to apply the strategies found to be effective in larger trials involving participants with stroke, MS, or PD, with or without a history of SARS-CoV-2 infection;
- to compare the outcomes of dual-task strategies with those obtained through conventional rehabilitation approaches.
The activities planned within the project will be distributed among the four participating operating units (OUs). OU1 (Santa Lucia Foundation) will be responsible for:
- designing and validating dual-task rehabilitation strategies covering the three possible combinations of motor and cognitive activities (dual motor task, dual cognitive task, and combined motor-cognitive task);
- assessing the feasibility of these strategies through a pilot study involving small groups of individuals with the aforementioned neurological conditions, including those with long-term outcomes of SARS-CoV-2 infection, and selecting the most suitable approaches.
All four OUs will participate in the selection and enrollment of subjects for the trial phase.
OUs 1, 3, and 4 (Collaborators to the project) will conduct the activities planned for the experimental trial, including:
- baseline assessment of enrolled participants using validated instruments to measure various motor and cognitive functions;
- implementation of rehabilitation strategies based on the dual-task approach, making use of newly emerging technological devices;
- follow-up assessments at the end of the treatment period and again three months later.
Assessments will focus on motor functions such as gait and balance, cognitive functions, mood, the occurrence of domestic accidents, and the measurement of circulating biomarkers of neuroinflammation and neurodegeneration.
Data collected throughout the different phases of the study will be compiled into a single database, and statistical analyses will be performed by researchers from OU1.
The interpretation of results will be carried out collaboratively by members of all OUs, and findings will be disseminated through participation in conferences and congresses, as well as through publications in peer-reviewed international indexed journals.
Read the detailed description
Summary Description
Neurological diseases such as Stroke Outcomes (SO), Multiple Sclerosis (MS), and Parkinson's disease (PD) cause complex and severe disabilities involving motor, cognitive, and autonomic domains. Widespread neuroinflammation contributes to progressive tissue damage in all three conditions. SARS-CoV-2 infection can further exacerbate neurological deficits through inflammatory mechanisms, and its long-term effects may aggravate pre-existing motor and cognitive impairments. Pharmacological therapies for these diseases-and for post-COVID neurological sequelae-offer limited benefit; therefore, neurorehabilitation represents a crucial therapeutic resource.
Dual-task approaches, which simultaneously target cognitive and motor functions, have gained increasing interest because they better reflect daily life demands, align with embodied cognition theories, and allow concurrent intervention on multiple deficit domains. However, their efficacy has not been adequately assessed in SO, MS, and PD, and has not been investigated at all in individuals with long-term neurological consequences of SARS-CoV-2. This project aims to design and validate dual-task rehabilitation strategies in these populations and compare their outcomes with those of conventional rehabilitation.
Background and State of the Art
Individuals with SO, MS, and PD share multifaceted disabilities and underlying neuroinflammatory processes. The additional impact of COVID-19, especially in cases with persistent neurological manifestations, emphasizes the urgency of effective rehabilitation methods. Preliminary work by the research team includes studies on dual-task mechanisms and implementation in clinical settings, confirming feasibility and theoretical relevance. Nonetheless, rigorous randomized, controlled-possibly double-blind-trials are required to determine clinical efficacy.
Project Activities and Organization
The project includes the following integrated activities:
Design and validation of dual-task rehabilitation strategies, encompassing:
- dual motor tasks
- dual cognitive tasks
- combined motor-cognitive tasks Virtual and/or augmented reality environments will be used when beneficial. Pilot feasibility study in small groups (5 per diagnostic category: SO, MS, PD, long-term post-COVID) to assess applicability, patient acceptance, and preliminary efficacy. Conducted by OU1.
Participant selection for the clinical trial (SO, MS, PD, with or without past SARS-CoV-2 infection) based on predefined inclusion/exclusion criteria. Conducted jointly by all OUs.
Randomized controlled trial, conducted by OU1, OU3, and OU4, including:
- Baseline motor, cognitive, and mood assessment using validated tools.
- Implementation of dual-task strategies alongside standard rehabilitation, using emerging technological devices.
- Re-assessment at treatment completion and at 3-month follow-up.
Data integration in a unified database (OU1). Statistical analyses and interpretation, including advanced methods such as artificial neural networks (OU1).
Dissemination through conferences and publications. Specific Aims Aim 1 - Development and feasibility testing of dual-task strategies
Dual-task interventions will be designed by OU1 based on the three task combinations. A preliminary feasibility phase will enroll 20 participants (5 SO, 5 MS, 5 PD, 5 post-COVID). Strategies demonstrating the best balance of efficacy and acceptability will be selected for the clinical trial.
Aim 2 - Application of validated strategies in a randomized controlled trial A total of 48 participants (16 SO, 16 MS, 16 PD) will be recruited; for each condition, half will have a history of SARS-CoV-2 infection with neurological symptoms persisting ≥4 weeks. Additional inclusion/exclusion criteria ensure safety and feasibility.
Participants will be randomized into:
- Experimental group: standard rehabilitation (3/week) with dual-task training (2/week, 30 min/session)
- Control group: standard rehabilitation with placebo low-resistance cycling (2/week, 30 min/session)
Aim 3 - Comparison of dual-task vs conventional rehabilitation outcomes
Outcome measures will be compared between:
- participants receiving standard with placebo therapy, and
- participants receiving standard with dual-task therapy.
Additionally, pre- and post-intervention blood samples will be analyzed for biomarkers of neuroinflammation and neurodegeneration, providing complementary insight into physiological changes associated with both rehabilitation modalities.
Appropriate statistical methods, including machine-learning-based analyses, will be used to evaluate between-group and within-group differences.
- Conditions
- Stroke, Multiple Sclerosis, Parkinson Disease, Dual Task Exercises, Long COVID
- Being tested
- Dual Task exercise, Physical therapy
- Keywords
- dual task, cognitive motor integration, neurological disease, validation
- Medical subject headings
- Stroke, Multiple Sclerosis, Parkinson Disease, Post-Acute COVID-19 Syndrome, Nervous System Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dual Task exerciseOther
Upper-limb sessions employ Virtual Art Therapy, during which the seated patient performs virtual painting tasks that simultaneously stimulate motor control and cognitive engagement. Balance training initially requires the patient to stand still with eyes closed-sometimes on unstable surfaces-while performing serial subtraction tasks, followed in later sessions by the Fukuda stepping test combined with the identification of male or female voices presented in congruent or incongruent sequences. Motor imagery sessions involve imagining the number of steps and time needed to reach a cone placed at varying distances before executing the actual movement. Gait training, conducted overground or on a treadmill, integrates various cognitive challenges: generating lists from semantic categories, recognizing objects or colors in the environment, repeating short word sequences for memory engagement, performing serial subtraction while walking, responding to directional auditory stimuli.
Physical therapyOther
Conventional exercises for upper and lower limbs motor rehabilitatiion
| Study group | Role | What they receive |
|---|---|---|
| Experimental Group (Dual Task training) | Experimental | The dual-task rehabilitation program includes a series of progressively complex activities targeting upper-limb function, balance, motor imagery, and gait. Receives: Other: Dual Task exercise |
| Control Group (conventional motor exercises) | Active comparator | Patients in the control group will perform stationary cycling (or an equivalent low-resistance aerobic activity) instead of the dual-task training. Receives: Other: Physical therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
6-Minute Walking Test
The 6-Minute Walking Test is a standardized assessment of functional walking capacity in which the patient is instructed to walk back and forth along a predefined path for six minutes. The total distance covered during this time reflects the individual's aerobic endurance, mobility, and overall functional performance. The test is simple, well tolerated, and widely used in both clinical and research settings. The minimum score is about 300m and denotes a very low funcional motility, while higher distance covered (> 600 m) is a sign of good walking ability.
Measured: Baseline (Day 1), end of treatment (Day 56), follow -up (146)
Secondary outcomes (1)
Montreal Cognitive Assessment
The Montreal Cognitive Assessment is a widely used screening tool designed to evaluate global cognitive function. It assesses multiple domains, including attention, executive functions, memory, language, visuospatial abilities, abstraction, and orientation. The test is quick to administer, sensitive to mild cognitive impairment, and commonly applied in both clinical practice and research settings. The maximum score is 30, 25 is a cut off for normal cognitive functioning, with higher score denoting better performance.
Measured: Baseline (Day 1), End of Treatment (Day 56), 3-Month Follow-up (Day 146)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Nov 2025
- Study start1 Nov 2025
- Primary completion30 Mar 2026 (estimated)
- Study completion28 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- I.R.C.C.S. Fondazione Santa Lucia
- Sponsor type
- University, hospital or other
- Collaborators
- Vito Fazzi Hospital, ASL Frosinone, Azienda Ospedaliera San Giovanni di Dio Ruggi d'Aragona
- Responsible party
- Sponsor
- Investigators
- Marco Iosa, PhD, Associate Professor, Principal investigator, IRRCS Santa Lucia foundation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07254377
- Sponsor's protocol ID
- PNRR-MCNT2-2023-12378271
- Acronym
- START
- Status last verified
- Jun 2025
- First submitted
- 19 Nov 2025
- Last updated
- 11 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- START: Design and Validation of Innovative Strategies Based on Dual-Task Approach for Neuro- Rehabilitation Technologically-supported in People With Chronic Neuro-inflammatory Disease
- ClinicalTrials.gov ID
- NCT07254377
- Acronym / sponsor ID
- START / PNRR-MCNT2-2023-12378271
- Conditions
- Stroke, Multiple Sclerosis, Parkinson Disease, Dual Task Exercises, Long COVID
- Keywords
- dual task, cognitive motor integration, neurological disease, validation
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- I.R.C.C.S. Fondazione Santa LuciaUniversity, hospital or other
- Collaborators
- Vito Fazzi Hospital, ASL Frosinone, Azienda Ospedaliera San Giovanni di Dio Ruggi d'Aragona
- Study start
- 1 Nov 2025 (actual)
- Primary completion
- 30 Mar 2026 (estimated)
- Study completion
- 28 Feb 2027 (estimated)
- First posted
- 28 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
People affected by Stroke, Multiple Sclerosis (MS), and Parkinson's disease (PD) share severe and complex disabilities. Widespread neuro-inflammatory processes represent an important pathogenetic component in all three conditions. The potential overlap with neurological complications of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has further contributed to the worsening of functional impairment. Since pharmacological therapies have limited or negligible effects in these disorders, neurorehabilitation plays a crucial role in restoring and maintaining adequate functional abilities. In this context, dual-task strategies have attracted growing interest, but their effectiveness has not been adequately assessed in the above neurological conditions-and not at all in individuals with long-term sequelae of SARS-CoV-2 infection.
Based on these premises, the objectives of this research project are:
- to design rehabilitation strategies using the dual-task approach in its various forms (dual motor task, dual cognitive task, and combined motor-cognitive task) and to conduct feasibility tests in small groups of individuals affected by stroke, MS, PD, or long-term Coronavirus Disease 2019 (COVID-19) sequelae;
- to apply the strategies found to be effective in larger trials involving participants with stroke, MS, or PD, with or without a history of SARS-CoV-2 infection;
- to compare the outcomes of dual-task strategies with those obtained through conventional rehabilitation approaches.
The activities planned within the project will be distributed among the four participating operating units (OUs). OU1 (Santa Lucia Foundation) will be responsible for:
- designing and validating dual-task rehabilitation strategies covering the three possible combinations of motor and cognitive activities (dual motor task, dual cognitive task, and combined motor-cognitive task);
- assessing the feasibility of these strategies through a pilot study involving small groups of individuals with the aforementioned neurological conditions, including those with long-term outcomes of SARS-CoV-2 infection, and selecting the most suitable approaches.
All four OUs will participate in the selection and enrollment of subjects for the trial phase.
OUs 1, 3, and 4 (Collaborators to the project) will conduct the activities planned for the experimental trial, including:
- baseline assessment of enrolled participants using validated instruments to measure various motor and cognitive functions;
- implementation of rehabilitation strategies based on the dual-task approach, making use of newly emerging technological devices;
- follow-up assessments at the end of the treatment period and again three months later.
Assessments will focus on motor functions such as gait and balance, cognitive functions, mood, the occurrence of domestic accidents, and the measurement of circulating biomarkers of neuroinflammation and neurodegeneration.
Data collected throughout the different phases of the study will be compiled into a single database, and statistical analyses will be performed by researchers from OU1.
The interpretation of results will be carried out collaboratively by members of all OUs, and findings will be disseminated through participation in conferences and congresses, as well as through publications in peer-reviewed international indexed journals.
Detailed description
Summary Description
Neurological diseases such as Stroke Outcomes (SO), Multiple Sclerosis (MS), and Parkinson's disease (PD) cause complex and severe disabilities involving motor, cognitive, and autonomic domains. Widespread neuroinflammation contributes to progressive tissue damage in all three conditions. SARS-CoV-2 infection can further exacerbate neurological deficits through inflammatory mechanisms, and its long-term effects may aggravate pre-existing motor and cognitive impairments. Pharmacological therapies for these diseases-and for post-COVID neurological sequelae-offer limited benefit; therefore, neurorehabilitation represents a crucial therapeutic resource.
Dual-task approaches, which simultaneously target cognitive and motor functions, have gained increasing interest because they better reflect daily life demands, align with embodied cognition theories, and allow concurrent intervention on multiple deficit domains. However, their efficacy has not been adequately assessed in SO, MS, and PD, and has not been investigated at all in individuals with long-term neurological consequences of SARS-CoV-2. This project aims to design and validate dual-task rehabilitation strategies in these populations and compare their outcomes with those of conventional rehabilitation.
Background and State of the Art
Individuals with SO, MS, and PD share multifaceted disabilities and underlying neuroinflammatory processes. The additional impact of COVID-19, especially in cases with persistent neurological manifestations, emphasizes the urgency of effective rehabilitation methods. Preliminary work by the research team includes studies on dual-task mechanisms and implementation in clinical settings, confirming feasibility and theoretical relevance. Nonetheless, rigorous randomized, controlled-possibly double-blind-trials are required to determine clinical efficacy.
Project Activities and Organization
The project includes the following integrated activities:
Design and validation of dual-task rehabilitation strategies, encompassing:
- dual motor tasks
- dual cognitive tasks
- combined motor-cognitive tasks Virtual and/or augmented reality environments will be used when beneficial. Pilot feasibility study in small groups (5 per diagnostic category: SO, MS, PD, long-term post-COVID) to assess applicability, patient acceptance, and preliminary efficacy. Conducted by OU1.
Participant selection for the clinical trial (SO, MS, PD, with or without past SARS-CoV-2 infection) based on predefined inclusion/exclusion criteria. Conducted jointly by all OUs.
Randomized controlled trial, conducted by OU1, OU3, and OU4, including:
- Baseline motor, cognitive, and mood assessment using validated tools.
- Implementation of dual-task strategies alongside standard rehabilitation, using emerging technological devices.
- Re-assessment at treatment completion and at 3-month follow-up.
Data integration in a unified database (OU1). Statistical analyses and interpretation, including advanced methods such as artificial neural networks (OU1).
Dissemination through conferences and publications. Specific Aims Aim 1 - Development and feasibility testing of dual-task strategies
Dual-task interventions will be designed by OU1 based on the three task combinations. A preliminary feasibility phase will enroll 20 participants (5 SO, 5 MS, 5 PD, 5 post-COVID). Strategies demonstrating the best balance of efficacy and acceptability will be selected for the clinical trial.
Aim 2 - Application of validated strategies in a randomized controlled trial A total of 48 participants (16 SO, 16 MS, 16 PD) will be recruited; for each condition, half will have a history of SARS-CoV-2 infection with neurological symptoms persisting ≥4 weeks. Additional inclusion/exclusion criteria ensure safety and feasibility.
Participants will be randomized into:
- Experimental group: standard rehabilitation (3/week) with dual-task training (2/week, 30 min/session)
- Control group: standard rehabilitation with placebo low-resistance cycling (2/week, 30 min/session)
Aim 3 - Comparison of dual-task vs conventional rehabilitation outcomes
Outcome measures will be compared between:
- participants receiving standard with placebo therapy, and
- participants receiving standard with dual-task therapy.
Additionally, pre- and post-intervention blood samples will be analyzed for biomarkers of neuroinflammation and neurodegeneration, providing complementary insight into physiological changes associated with both rehabilitation modalities.
Appropriate statistical methods, including machine-learning-based analyses, will be used to evaluate between-group and within-group differences.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental Group (Dual Task training) | Experimental | Other: Dual Task exerciseThe dual-task rehabilitation program includes a series of progressively complex activities targeting upper-limb function, balance, motor imagery, and gait. |
| Control Group (conventional motor exercises) | Active comparator | Other: Physical therapyPatients in the control group will perform stationary cycling (or an equivalent low-resistance aerobic activity) instead of the dual-task training. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Diagnosis of stroke outcomes, Multiple Sclerosis (MS), or Parkinson's disease (PD).
- For stroke outcomes: patients must be able to walk independently for at least 6 minutes without resting.
- For MS: diagnosis according to the 2017 revised McDonald criteria; relapsing-remitting or secondary progressive forms; age 25-65 years; Expanded Disability Status Scale score between 2.5 and 6.0.
- For PD: idiopathic Parkinson's disease.
- For each neurological condition, half of the participants must have had Severe Acute Respiratory Syndrome Coronavirus 2 infection with neurological symptoms attributable to CNS involvement lasting at least 4 weeks.
Key exclusion criteria (4 listed)
- Cognitive or motor comobidity;
- Severe visual or hearing impairments that may compromise understanding of exercises
- Language impairments, such as aphasia
- Inability to walk independently
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dual Task exerciseUpper-limb sessions employ Virtual Art Therapy, during which the seated patient performs virtual painting tasks that simultaneously stimulate motor control and cognitive engagement. Balance training initially requires the patient to stand still with eyes closed-sometimes on unstable surfaces-while performing serial subtraction tasks, followed in later sessions by the Fukuda stepping test combined with the identification of male or female voices presented in congruent or incongruent sequences. Motor imagery sessions involve imagining the number of steps and time needed to reach a cone placed at varying distances before executing the actual movement. Gait training, conducted overground or on a treadmill, integrates various cognitive challenges: generating lists from semantic categories, recognizing objects or colors in the environment, repeating short word sequences for memory engagement, performing serial subtraction while walking, responding to directional auditory stimuli. | Other | Experimental Group (Dual Task training) |
| Physical therapyConventional exercises for upper and lower limbs motor rehabilitatiion | Other | Control Group (conventional motor exercises) |
Primary outcome
6-Minute Walking Test
Time frame: Baseline (Day 1), end of treatment (Day 56), follow -up (146)
The 6-Minute Walking Test is a standardized assessment of functional walking capacity in which the patient is instructed to walk back and forth along a predefined path for six minutes. The total distance covered during this time reflects the individual's aerobic endurance, mobility, and overall functional performance. The test is simple, well tolerated, and widely used in both clinical and research settings. The minimum score is about 300m and denotes a very low funcional motility, while higher distance covered (> 600 m) is a sign of good walking ability.
1 secondary outcome
Montreal Cognitive Assessment
Time frame: Baseline (Day 1), End of Treatment (Day 56), 3-Month Follow-up (Day 146)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marco Iosa, PhD, Associate Professor principal investigator
IRRCS Santa Lucia foundation
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dual Task exercise and Physical therapy in people with Stroke and Multiple Sclerosis, run by I.R.C.C.S. Fondazione Santa Lucia at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 11 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
6-Minute Walking Test (time frame: Baseline (Day 1), end of treatment (Day 56), follow -up (146)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Dec 2025.